Applications and Pipelines

MonoTx’s platform supports a diversified pipeline spanning ophthalmology, neurology, wound healing, anti-aging, and research tools. 

Therapeutic Area

Pipeline

Lead Indications

Stage

Ophthalmology — Ocular Surface

ERP® Eye Drops

Dry eye, limbal stem cell deficiency, persistent epithelial defects, ocular GVHD, Stevens-Johnson syndrome

Preclinical (in vivo PoC demonstrated)

Ophthalmology — Aging Eye

ERP® Intravitreal Injection

Glaucoma, age-related macular degeneration, cataract, retinitis pigmentosa

Preclinical (in vivo PoC demonstrated)

Ophthalmology — Sustained Release

Exosome-HAMA Microspheres

Glaucoma (neuroprotection + sustained intraocular release)

Formulation development

Neurology

UCB MNC / RCF (IV Infusion)

Hypoxic-ischemic encephalopathy (HIE), neonatal stroke, cerebral palsy

Preclinical (in vivo PoC demonstrated)

Wound Healing & Dermatology

ERP® + rFN Topical Gel

Chronic wounds (diabetic ulcers, pressure sores), surgical incisions, burns, scar management

Preclinical (in vivo PoC demonstrated)

Anti-Aging

ERP® / miR-26a-5p Mimic

Multi-organ cellular senescence; aesthetic skincare; fertility enhancement (IVF)

Discovery / Early preclinical

Aesthetics (Revenue-Generating)

ERP® Supply

Aesthetic and skincare products

Commercial — generating near-term revenue

Mononuclear Cells (MNC)

MonoTx®, cord blood MNCs are used to treat people with chronic spinal cord injury as well as research material for pre-clinical (animal) studies to develop therapies for hypoxia-ischemia encephalopathy, acute and chronic stroke, and age-related macular degeneration.

Spinal Cord Injury

Phase I–II clinical trial: assessing the safety and efficacy of umbilical cord blood mononuclear cell transplant therapy for chronic complete spinal cord injury.

Phase II clinical trial: transplantation of umbilical cord blood mononuclear cells (UCBMNC) followed by intensive rehabilitation to recover long distance ambulation, bowel and bladder function in patients with chronic spinal cord injury.

Acute Cerebral Stroke

We will carry out two clinical trials, one to assess the effect of the cord blood on acute stroke and the other on chronic stroke.  All the subjects will receive intensive rehabilitation and locomotor training after treatment.  The dose given will depend on the location and size of the brain infarct.

HIE

Phase I trial: Assessing Feasibility and Safety of Umbilical Cord Blood Transfusion in the Treatment of Neonatal Cerebral Ischemia and Anemia.

Infusion of autologous blood cells collected from the cord and placenta at the time of birth to treat hypoxia ischemia of newborn baby.